Your browser doesn't support javascript.
loading
Incidence of SCID in Germany from 2014 to 2015 an ESPED* Survey on Behalf of the API*** Erhebungseinheit für Seltene Pädiatrische Erkrankungen in Deutschland (German Paediatric Surveillance Unit) ** Arbeitsgemeinschaft Pädiatrische Immunologie.
Shai, Sonu; Perez-Becker, Ruy; Andres, Oliver; Bakhtiar, Shahrzad; Bauman, Ulrich; von Bernuth, Horst; Classen, Carl-Friedrich; Dückers, Gregor; El-Helou, Sabine M; Gangfuß, Andrea; Ghosh, Sujal; Grimbacher, Bodo; Hauck, Fabian; Hoenig, Manfred; Husain, Ralf A; Kindle, Gerhard; Kipfmueller, Florian; Klemann, Christian; Krüger, Renate; Lainka, Elke; Lehmberg, Kai; Lohrmann, Florens; Morbach, Henner; Naumann-Bartsch, Nora; Oommen, Prasad Thomas; Schulz, Ansgar; Seidemann, Kathrin; Speckmann, Carsten; Sykora, Karl-Walter; von Kries, Rüdiger; Niehues, Tim.
Afiliación
  • Shai S; Department of Paediatrics, Helios Klinikum Krefeld, Krefeld, Germany. sonu.shai@helios-gesundheit.de.
  • Perez-Becker R; Department of Paediatrics, Helios Klinikum Krefeld, Krefeld, Germany.
  • Andres O; Department of Paediatrics, University Hospital Würzburg, Würzburg, Germany.
  • Bakhtiar S; Department for Children and Adolescents, Division for Stem Cell Transplantation and Immunology, Frankfurt University Hospital, Frankfurt a.M., Germany.
  • Bauman U; Department of Paediatric Pneumology, Allergy and Neonatology, Hannover Medical School, Hannover, Germany.
  • von Bernuth H; Department of Paediatric Pneumology, Immunology and Intensive Care, Charité- Universitätsmedizin, Berlin, Germany.
  • Classen CF; Department of Immunology, Labor Berlin GmbH, Berlin, Germany.
  • Dückers G; Berlin-Brandenburg Center for Regenerative Therapies, Berlin, Germany.
  • El-Helou SM; Department for Children and Adolescents, Oncology Hematology Division, University Medicine Rostock, Rostock, Germany.
  • Gangfuß A; Department of Paediatrics, Helios Klinikum Krefeld, Krefeld, Germany.
  • Ghosh S; Institute for Immunodeficiency, Center for Chronic Immunodeficiency (CCI), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Grimbacher B; RESIST - Cluster of Excellence 2155 to Hanover Medical School, University of Freiburg, Freiburg, Germany.
  • Hauck F; Department of Clinical Immunology and Rheumatology, Hanover Medical School, Hanover, Germany.
  • Hoenig M; Cluster of Excellence RESIST (EXC 2155), Hanover Medical School, Carl-Neuberg-Straße 1, 30625, Hanover, Germany.
  • Husain RA; Children's Hospital, University Duisburg-Essen, Essen, Germany.
  • Kindle G; Department of Paediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Centre for Child and Adolescent Health, University of Düsseldorf, Düsseldorf, Germany.
  • Kipfmueller F; Institute for Immunodeficiency, Center for Chronic Immunodeficiency (CCI), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Klemann C; RESIST - Cluster of Excellence 2155 to Hanover Medical School, University of Freiburg, Freiburg, Germany.
  • Krüger R; DZIF - German Center for Infection Research, Satellite Center Freiburg, Freiburg, Germany.
  • Lainka E; CIBSS - Centre for Integrative Biological Signalling Studies, University of Freiburg, Freiburg, Germany.
  • Lehmberg K; Department of Paediatrics, Dr. von Hauner Children's Hospital, University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.
  • Lohrmann F; Department of Paediatrics, University Medical Centre Ulm, Ulm, Germany.
  • Morbach H; University Children's Hospital, Jena, Germany.
  • Naumann-Bartsch N; Institute for Immunodeficiency, Center for Chronic Immunodeficiency (CCI), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Oommen PT; FREEZE Biobank, Center for Biobanking, Medical Center, University of Freiburg, Freiburg, Germany.
  • Schulz A; Department of Neonatology and Paediatric Critical Care, University Children's Hospital Bonn, Bonn, Germany.
  • Seidemann K; Department of Paediatric Pneumology, Allergy and Neonatology, Hannover Medical School, Hannover, Germany.
  • Speckmann C; Department of Paediatric Pneumology, Immunology and Intensive Care, Charité- Universitätsmedizin, Berlin, Germany.
  • Sykora KW; Children' s Hospital, University Duisburg-Essen, Paediatric Rheumatology, Essen, Germany.
  • von Kries R; Division of Paediatric Stem Cell Transplantation and Immunology, University Medical Center Hamburg Eppendorf, Hamburg, Germany.
  • Niehues T; University Medical Center Freiburg, Freiburg in Br., Germany.
J Clin Immunol ; 40(5): 708-717, 2020 07.
Article en En | MEDLINE | ID: mdl-32458183
PURPOSE: Severe combined immunodeficiencies (SCID) are a heterogeneous group of fatal genetic disorders, in which the immune response is severely impaired. SCID can be cured if diagnosed early. We aim to determine the incidence of clinically defined SCID cases, acquire data of reported cases and evaluate their possible prediction by newborn screening, before introduction of a general screening program in Germany. METHODS: The German Surveillance Unit for rare Paediatric Diseases (ESPED) prospectively queried the number of incident SCID cases in all German paediatric hospitals in 2014 and 2015. Inclusion criteria were (1) opportunistic or severe infections or clinical features associated with SCID (failure to thrive, lacking thymus or lymphatic tissue, dysregulation of the immune system, graft versus host reaction caused by maternal T cells), (2) dysfunctional T cell immunity or proof of maternal T cells and (3) exclusion of a secondary immunodeficiency such as human immunodeficiency virus (HIV) infection. In a capture-recapture analysis, cases were matched with cases reported to the European Society for Immunodeficiencies (ESID). RESULTS: Fifty-eight patients were initially reported to ESPED, 24 reports could be confirmed as SCID, 21 patients were less than 1 year old at time of diagnosis. One SCID case was reported to ESID only. The estimated incidence of SCID in Germany is 1.6/100,000 (1:62,500) per year in children less than 1 year of age. Most patients reported were symptomatic and mortality in regard to reported outcome was high (29% (6/22)). The majority of incident SCID cases were considered to be probably detectable by newborn screening. CONCLUSIONS: SCID is a rare disease with significant mortality. Newborn screening may give the opportunity to improve the prognosis in a significant number of children with SCID.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Inmunodeficiencia Combinada Grave Tipo de estudio: Incidence_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Female / Humans / Infant / Male / Newborn País/Región como asunto: Europa Idioma: En Revista: J Clin Immunol Año: 2020 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Inmunodeficiencia Combinada Grave Tipo de estudio: Incidence_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Female / Humans / Infant / Male / Newborn País/Región como asunto: Europa Idioma: En Revista: J Clin Immunol Año: 2020 Tipo del documento: Article País de afiliación: Alemania